Last reviewed · How we verify

Lispro-insulin — Competitive Intelligence Brief

Lispro-insulin (Lispro-insulin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Rapid-acting insulin analog. Area: Diabetes.

marketed Rapid-acting insulin analog Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Lispro-insulin (Lispro-insulin) — University of Roma La Sapienza. Lispro-insulin is a rapid-acting insulin analog that binds to insulin receptors to promote glucose uptake and utilization in peripheral tissues.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Lispro-insulin TARGET Lispro-insulin University of Roma La Sapienza marketed Rapid-acting insulin analog Insulin receptor
Tresiba INSULIN DEGLUDEC Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2015-01-01
Levemir INSULIN DETEMIR Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2005-01-01
Apidra INSULIN GLULISINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2004-01-01
Novolog INSULIN ASPART Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Lantus INSULIN GLARGINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Humalog INSULIN LISPRO Eli Lilly marketed Insulin Analog [EPC] Insulin receptor 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Rapid-acting insulin analog class)

  1. Eli Lilly and Company · 12 drugs in this class
  2. Sanofi · 6 drugs in this class
  3. Novo Nordisk A/S · 4 drugs in this class
  4. Rigshospitalet, Denmark · 2 drugs in this class
  5. Mountain Diabetes and Endocrine Center · 1 drug in this class
  6. Mylan Inc. · 1 drug in this class
  7. Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
  8. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 1 drug in this class
  9. Oxford University Hospitals NHS Trust · 1 drug in this class
  10. Tel-Aviv Sourasky Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lispro-insulin — Competitive Intelligence Brief. https://druglandscape.com/ci/lispro-insulin. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: